Use of the aminoalkylindole JWH-073-M4 and related compounds as neutral CB1 receptor antagonists for the treatment of alcoholism, drug abuse, obesity, and obesity-related diseases
Novel alkylindoles that bind tightly to cannabinoid receptors and are neutral antagonists for the cannabinoid 1 receptor and agonists for the cannabinoid 2 receptor are provided. These compounds are useful for treating alcoholism and drug abuse and for treating obesity.
1. A composition comprising a compound of formula III:
wherein R 1 is 5-O-methyl, 7-O-methyl, or 7-OH;
R 2 is C 1 -C 6 linear alkyl;
and R 3 is
2. The composition of claim 1 wherein the R 2 is n-butyl.
3. The composition of claim 1 wherein R 1 is 7-O-methyl.
4. The composition of claim 1 wherein R 3 is
5. The composition of claim 1 wherein the compound has a K D for CB1R and CB2R of less than 1 micromolar.
6. The composition of claim 5 wherein the compound has a K D for CB1R and CB2R of less than 100 nM.
7. The composition of claim 1 wherein the compound is a neutral CB1R antagonist.
8. The composition of claim 1 wherein the compound is a CB2R agonist.
9. The composition of claim 1 wherein the compound is TV-5-249 or TV-6-41.
10. The composition of claim 1 wherein the composition is a pharmaceutical composition.
11. The composition of claim 10 wherein the pharmaceutical composition is a sterile solution for injection.
12. The composition of claim 10 wherein the pharmaceutical composition is tablet, capsule, gel cap, or pill for oral administration.
13. The composition of claim 10 wherein the pharmaceutical composition is a unit dosage composition for treating alcoholism or drug abuse in a human.
14. A method of treating alcohol or drug abuse in a human comprising:
administering a compound of formula III in an amount and for a time effective to treat alcohol or drug abuse in a human in need thereof:
wherein R 1 is 5-O-methyl, 7-O-methyl, or 7-OH;
R 2 is C 1 -C 6 linear alkyl;
and R 3 is
15. The method of claim 14 wherein the compound is TV-5-249 or TV-6-41.